Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome

In a placebo-controlled study, denileukin diftitox (DD) was effective against cutaneous T-cell lymphoma (CTCL) expressing CD25. An open-label companion study examined the efficacy and safety of DD in 36 patients with skin biopsies containing < 20% CD25 cells by immunohistochemistry staining (CD25...

Full description

Saved in:
Bibliographic Details
Main Authors: Prince, H. Miles, Martin, Ann G., Olsen, Elise A., Fivenson, David P., Duvic, Madeleine
Format: Artigo
Language:Inglês
Published: Informa Healthcare 2013
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3523809/
https://ncbi.nlm.nih.gov/pubmed/22738414
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2012.706286
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items